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Abstract
Background and Objectives: Nicaragua is highly endemic for hepatitis A. We aimed to provide an estimate of the change in
the age-specific risk of hepatitis A virus (HAV) infection based on serological data from cross-sectional and longitudinal
samples collected in Leo´n, Nicaragua, in 1995/96 (n = 979) and 2003 (n = 494).
Methods: The observed age-specific prevalence of anti-HAV antibodies was correlated to the age-specific risk of infection
by calculating the probability of freedom from infection at a specific age.
Results: The proportion of seropositive children aged 1.5 to 6 years was 42% in 2003 compared to 67% in 1995/96.
Estimated annual risk of infection for a 3-year old child was 30% (95% CI: 27.0%, 33.1%) in 1995 and 15.5% (95% CI: 12.4%,
19.0%) in 2003. There was good agreement between estimates based on cross-sectional and longitudinal data. The age-
specific geometric mean of the quantified anti-HAV antibody levels assessed in 2003 was highest at age 4 and decreased
steadily up to age 40.
Conclusions: The substantially lower risk of HAV infection in 2003 than in 1995 for young children indicates a beginning
transition from high to intermediate endemicity in Leo´n, Nicaragua. Consecutive age-stratified serosurveys are useful to
assess changes in risk of infection following public health interventions. The decreasing age-specific GMC of anti-HAV
antibodies during adulthood in a country with endemic HAV indirectly suggests that ongoing HAV exposure in the
community has marginal boosting effect on antibody levels once protective immunity has been established by natural
infection.
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Introduction
An estimated 212 million cases of hepatitis A virus (HAV)
infection [1] and 31 million cases of symptomatic illness
(S.Wiersma, personal communication) occurred worldwide in
2005, with some 35,000 estimated deaths [1]. The clinical
presentation depends on the age at infection. In children younger
than 6 years, hepatitis A is usually asymptomatic, while most
adolescents or adults develop moderate to severe symptoms and
jaundice [1,2]. Because HAV infection confers life-long immunity,
seroprevalence rates in different age groups are indicators of
susceptibility to infection in a population [2,3]. In areas of high
endemicity, with a life-time risk of infection above 90% [1], most
HAV infections occur in early childhood and clinical symptoms of
hepatitis A are rarely seen. In areas of low endemicity, mainly
adolescents and adults are infected. It follows that epidemics of
clinically manifest HAV infection are uncommon in highly
endemic areas whereas in areas with intermediate endemicity,
hepatitis A infections occur primarily as outbreaks [4].
Universal childhood hepatitis A vaccination is an effective
means to control HAV infections in a given population, whereby -
due to herd immunity - the morbidity not only of the target toddler
population but also of the older children and of the adult
population declines to low levels within a few years [5,6].
Improving socioeconomic conditions in developing countries
alone result in a transition from high to intermediate endemicity,
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with an increased number of susceptible individuals at higher ages
[2,3,7]. The understanding of such transitions in conjunction with
the shift in age-related risk of infection is crucial in predicting
HAV transmission patterns and for decisions on appropriate
prevention strategies [1,8,9].
Nicaragua is a country with high endemicity and low burden of
clinical HAV as most infections are asymptomatic [10]. The aim
of the present analysis was to provide an estimate on the changes
in the age-specific risk of hepatitis A infection, based on age-
specific seroprevalence data collected in Leo´n, Nicaragua, in 1995
and 2003. We show that the conduct of repeated cross-sectional
surveys providing estimates of age-specific HAV antibody
prevalence can be used to estimate the force of infection in a
given population and might be used to monitor public health
interventions.
Methods
Study populations and data sources
Seroprevalence of anti-HAV antibodies was determined from
analyses of samples collected in two studies conducted in 1995/96
and 2003, respectively, in the same deprived area of Nicaragua’s
second city Leo´n. The first study was a placebo-controlled,
randomized, field efficacy study of a virosome hepatitis A vaccine
in children aged 1.5 to 6 years [10]. Serum samples were collected
from all screened children (cross-sectional sample 1995). Longitu-
dinal serological data from the seronegative children enrolled into
the placebo group of the field trial were also analyzed, with venous
blood drawn at week 6 and at months 3, 6, 9, 12, 15, and 18
(longitudinal sample 1995/96) [10]. In the 2003 study, serum
samples were collected from individuals aged 0.5 to 40 years
enrolled into a population-based serosurvey (cross-sectional sample
2003). In both cross-sectional studies data on age and sex had been
collected. Data on sanitary and socio-economic conditions
(number of household members, number of rooms, availability
of indoor water and flush toilet) were collected upon enrollment
into the 1995/96 longitudinal and the 2003 cross-sectional study
using a standardized questionnaire.
Ethics Statement
Both studies had been performed in accordance with the
Declaration of Helsinki and Good Clinical Practice and the study
protocols had been approved by the local ethics committee
(Comite´ de E´tica para investigaciones biomedicas (CEIB),
Universidad Nacional Auto´noma de Nicaragua (UNAN), Facultad
de Ciencias Me´dicas, Leo´n). Written informed consent was
obtained prior to any study related activities from the parents or
guardians on the behalf of the minors and children participating in
the 1995/96 hepatitis A vaccine field efficacy study and the 2003
serosurvey and from the adult subjects themselves in the 2003
serosurvey. The ethics committee had approved the consent
procedure.
Laboratory tests
In the seroepidemiology study 2003 anti-HAV antibodies were
quantified with the microparticle enzyme immunoassay HAVAB
2.0 Quantitative of the AXSYM system (Abbott Diagnostics
Division, Wiesbaden, Germany), with a lower limit of detection of
$10 mIU/mL. For the purpose of screening (field study 1995/96)
only qualitative analyses were carried out using the Enzygnost Anti
HAV test (Behring, Marburg, Germany) with a cut-off level of
$20 mIU/mL, as described earlier [10]. Both immunoassays used
the WHO standard anti-HAV serum as reference.
Statistical methods
In addition to seroprevalence rates in the 1995/96 and 2003
samples, the age group-specific geometric mean antibody concen-
trations (GMC) and minimum and maximum anti-HAV antibody
levels were extracted from the cross-sectional serology data of the
2003 survey. GMCs were calculated from the log-transformed
antibody concentration values of the anti-HAV antibody positive
individuals for the various age groups.
In the analysis of the 1995/96 and 2003 cross-sectional
prevalence data children ,1 year old were excluded because
their antibody results (low levels of 12–653 mIU/ml) do not
represent the cumulative risk of infection in the first year of life
but, reflect – as documented with other infant data from Leo´n [11]
- the presence of maternal antibodies. As described in detail by
others [12,13,14], the observed age-specific prevalence of anti-
HAV antibodies is a function of the age-specific annual risk of
infection. Similar to survival analysis, the relationship can be
expressed as the probability to remain free of infection up to a
given age A. For example, the probability to remain free of
infection in the second year of life is equal to 1 minus the annual
risk of infection in the second year of life (denoted as riskage(1 to
2)). The formula is as follows:
Probability free of infection at age Að Þ
~ 1riskage 0 to 1ð Þð Þ  . . .  1riskage A1 to Að Þð Þ
In a next step, we allowed the risk of infection to vary by age,
sex and time of survey. This was done by modeling the logit of the
annual risk of infection as a function of age (quadratic), sex (an
indicator variable for male versus female), and calendar year (an
indicator variable for 1995 vs. 2003) [12,13,14]. The model was
fitted to the cross-sectional seroprevalence data of the years 1995
and 2003 to obtain estimates of the age-specific risk of infection
using Markov chain Monte Carlo methods implemented in
WinBUGS 1.4.
Serological data from the longitudinal sample were used to
obtain direct estimates of the age-specific risk of HAV infection by
splitting of the follow-up time until seroconversion for each subject
over age strata. Direct estimates of annual infection risk were
compared to those from the cross-sectional samples.
Results
The two cross-sectional serosurveys consisted of samples
collected in 1995 from 979 children aged 1.5 to ,7 years
screened for the vaccine field trial [10] and of 496 individuals
(including 231 children aged 1 to ,7 years) who took part in the
2003 serosurvey. The longitudinal sample comprised consecutive
3-monthly sera from 117 children aged 1.3 to 5.9 years who in the
course of the field trial 1995/96 [10] had received placebo.
Demographic and socio-economic data are shown in Table 1.
Groups were balanced with respect to sex and the availability of
flush toilets. Crowding and the availability of indoor water were
somewhat lower in the 2003 cross-sectional compared to the
1995/1996 longitudinal study. None of the participants enrolled
and tested in the 2003 serosurvey had been vaccinated against
hepatitis A.
Seroprevalence
The age-specific seroprevalence of naturally acquired anti-HAV
antibodies is shown in Table 2. Seroprevalence rates and risk of
infection were lower in the population sampled in 2003 than in
Hepatitis A Serosurveys, Nicaragua
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children surveyed in 1995. In 1995, 67% of children aged 1.5 to
,7 years were anti-HAV positive with the proportion of
seropositive children increasing from 51% at the age of 2 years
to 87% at the age of 6 years. In 2003, seroprevalence in the same
age group overall was 42% and the proportion of seropositive
children increased from 23% at the age of 2 years to 62% at the
age of 6 years.
Annual risk of HAV infection
The estimated annual risk of infection for a 3-year old child was
30% (95% CI 27.0% to 33.1%) in 1995 compared with 15.5%
(95% CI 12.4% to 19.0%) in 2003 (Figure 1). There was no
difference between female and male sex in the risk of infection
(adjusted odds ratio [OR] male vs. female = 1.0 [95% CI 0.87 to
1.18]). However, calendar year had a significant effect, with a
Table 1. Socio-demographic data of individuals included in the cross-sectional and longitudinal samples.
1995 1995/96 2003
cross-sectional longitudinal cross-sectional
Total number of subjects included 974* 117 496**
Sex, No (%) male 496 (50.9) 60 (51.3) 244 (49.2)
female 478 (49.1) 57 (48.7) 252 (50.8)
No by age (mean age; range) 1–,7 years 974 (3.42; 1.4–6.1) 117 (2.95; 1.3–5.9) 231 (3.1; 1.0–6.0)
7–11 years n.a. n.a. 37 (9.6; 7.2–11.9)
12–16 years n.a. n.a. 33 (14.1; 12.0–16.2)
18–25 years n.a. n.a. 56 (22.1; 17.9–25.7)
26–33 years n.a. n.a. 56 (30.2; 26.1–33.8)
34–40 years n.a. n.a. 53 (38.4; 34.0–40.7)
No of inhabitants per room (mean 6 sd)***1–,7 years n.a. 4.062.3 3.662.1
Indoor water (%)*** 1–,7 years n.a. 106 (90.6) 187 (81.0)
Flush toilet (%)*** 1–,7 years n.a. 42 (35.9) 77 (33.3)
n.a. = not applicable or not assessed.
*For 5 out of 979 children enrolled (field trial screening12) the exact age was not known.
**Includes 30 infants (,1 year of age).
***In households with children 1–,7 years.
doi:10.1371/journal.pone.0087643.t001
Table 2. Seroprevalence of naturally acquired anti-HAV
antibodies in the cross-sectional samples from 1995 and 2003.
Seroprevalence n/N (%)
Age groups 1995* (n=974) 2003** (n=494***)
6–11 months n.a. 14/30 (46.7) #
12–17 months n.a. 4/34 (11.8) ø
18–23 months 48/126 (38.1) 3/28 (10.7)
24–29 months 58/113 (51.3) 7/29 (24.1)
30–35 months 83/145 (57.3) 12/35 (34.3)
36–47 months 170/232 (73.3) 15/33 (45.5)
48–59 months 150/189 (79.4) 23/38 (60.5)
60–71 months 148/169 (87.6) 20/32 (62.5)
7–11 years n.a. 32/37 (86.5)
12–16 years n.a. 32/34 (94.1)
18–25 years n.a. 56/56 (100)
26–33 years n.a. 56/56 (100)
34–40 years n.a. 53/53 (100)
*$20 mIU/mL anti-HAV antibodies (ELISA Enzygnost Anti HAV Behring).
**$10 mIU/mL anti-HAV antibodies (HAVAB 2.0 quantitative EIA AxSYM
Abbott).
***For two children (age group 18–23 months) no anti-HAV data were available.
#All 14 children had maternal anti-HAV antibodies (range; 12–653 mIU/mL).
ø1 child of 4 children had recent HAV infection (13700 mIU/mL), 3 children had
maternal antibodies (26, 28, and 31 mIU/mL).
n.a. = not applicable.
doi:10.1371/journal.pone.0087643.t002
Figure 1. Estimated age-specific risk (95% confidence inter-
vals) of HAV infection based on cross-sectional samples. Solid
circles represent estimates derived from the 1995 survey; open circles
are estimates from the 2003 data.
doi:10.1371/journal.pone.0087643.g001
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lower risk of infection for children in the 2003 cohort (OR 2003 vs.
1995= 0.43 [95% CI 0.32 to 0.54]).
Analysis of the longitudinal data obtained from the placebo
group of the 1995 study showed an annual 25% (95% CI 14% to
46%) risk of infection for a 3-year old child (Figure 2). There was
good agreement between the estimated annual risk of infection
from the longitudinal and cross-sectional studies in the 1995/96
samples, with the exception of 4-year old children in whom the
longitudinal data indicated a lower risk of infection compared with
that calculated from the cross-sectional sample (Figure 2).
Quantitative anti-HAV levels
Figure 3 shows for the 2003 serosurvey the age-specific
seroprevalence in age groups ranging from 6 to 11 months up to
34 to 40 years along with the GMC values and maximum values of
anti-HAV antibodies. In the younger age groups, seroprevalence
and GMC increased first in parallel, with GMC values leveling off
at age 4 to 5 years and then declining steadily until age 34 to 40
years. From the age group 12 to 16 years onwards seroprevalence
reached 94% and then remained at 100%. Very high maximal
concentrations of up to 450,000 mU/mL were recorded in
children and adolescents aged 5 to 16 years.
Discussion
In Nicaragua and many other low-income and middle-income
countries, public health-measures to reduce intestinal and
respiratory infections and malnutrition, which are responsible for
a high infant mortality rate, must take precedence over measures
to control HAV [15]. Improved socioeconomic and sanitary
conditions, including access to clean drinking water, reduce the
risk of HAV-infection [16]. These improvements change the
epidemiology of hepatitis A from high towards intermediate
endemicity, with a shift in the age of infection towards older age
groups and more clinically manifest disease [7,17]. Our study
comparing seroprevalence rates and risk of infection between 1995
and 2003 document this change for a deprived urban area in
Nicaragua. Furthermore, it shows that consecutive serosurveys are
a useful tool to assess the impact of public health measures on
populations at risk.
An understanding of epidemiological patterns and shifts is
essential for decisions on disease management and vaccination
strategies [9]. Because endemicity may vary between regions and
populations, estimates of epidemiological patterns are best
generated based on samples from the same population at different
time points. In our analysis we used both cross-sectional and
longitudinal data on the seroprevalence of anti-HAV antibodies in
residents of an area of Leo´n, Nicaragua with high hepatitis A
endemicity [10,18]. Using two cross-sectional surveys and
assuming a constant and identical period effect for all age groups,
we estimated a substantially lower risk of HAV infection in 2003
than in 1995. This decrease in infection risk is most likely due to
incremental improvements in socio-economic standards and
sanitary conditions, possibly paired with increased observation of
hygiene in a population exposed to hepatitis A vaccine trials and
other clinical studies for nearly one decade. The estimate for 1995
was in line with the results based on longitudinal data for children
aged #3 years. An outlier was the risk in children aged 4, where
the longitudinal 1995–96 data indicated a much lower risk
compared with all other samples studied. This discrepancy might
be explained by the fact that all children enrolled in the placebo
arm of the trial had to be seronegative. The older children had to
remain uninfected till age 4 and thus might have been at lower risk
of HAV infection and therefore might not have been represen-
tative of all children of that age in the community.
In our 2003 population, seroprevalence rates were 100% for all
age groups $18 years. Changes from high towards intermediate
endemicity of hepatitis A will eventually lead to an increased
proportion of susceptible adolescents and adults, especially in
urban areas with higher socioeconomic standards [1,17]. More-
over, infection rates are usually lower in urban than in rural areas
[18]. It has been suggested that, in these circumstances,
populations might benefit from vaccination against HAV [1,19].
Routine vaccination of toddlers has been shown to be an effective
approach to control hepatitis A in areas and countries shifting
from high to intermediate or from intermediate to low endemicity
[5,6,20,21,22,23,24].
A strength of the current analysis was the quantification of anti-
HAV antibody levels assessed in the 2003 cross-sectional
serosurvey. To our knowledge such quantitative data (Figure 3)
have not been provided in surveys of seroprevalence, which
typically report only percentages of seropositive individuals in a
population. The large variation in GMC as well as the very high
levels of anti-HAV antibodies were notable. Although the time
points of the individual HAV infection in our population are not
known, it can be inferred from the results that anti-HAV antibody
levels may reach half a million mIU/mL during acute infections. It
would be informative to compare our data with data from other
areas and countries, but for this to be possible, absolute antibody
values (mIU/ml) would need to be reported in addition to
seroprevalence rates in similar studies.
In the 100% seroprevalent adult population there was a steady
reduction in GMC with increasing age (Figure 3). In an area of
high endemicity such as Le´on, this observation of slowly declining
antibody levels over the age range of 12 to 40 years provides
indirect evidence of a solid infection-induced immunity. As
individuals living in a high endemicity area will repeatedly be
coming into contact with circulating HAV during adulthood - as
documented in a recent survey for Leo´n (unpublished data) -, our
findings suggest that such exposures have no boosting effect on
antibody levels once protective immunity has been established by
Figure 2. Estimated age-specific risk (95% confidence inter-
vals) of HAV infection in 1995 from cross-sectional and
longitudinal samples. The solid circles represent estimates derived
from the cross-sectional 1995 survey and open circles the estimates
from the longitudinal data.
doi:10.1371/journal.pone.0087643.g002
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natural infection. In other words, no wild virus encounters may be
needed to maintain a solid, life-long immune protection following
natural infection. This finding from a high endemicity area is
novel and seems to contradict the postulated role of natural
boosting in maintaining long-term immunity for certain vaccine-
preventable infections [25]. For example, the reduction in
antibody concentrations found in Israeli toddlers soon after the
introduction of universal mass vaccination against hepatitis A was
interpreted as reflecting reduced natural boosting after the rapid
reduction in circulating virus [6]. Of note, the so far successful
single-dose toddler vaccination program initiated 2005 in
Argentina [2,26] indicates a similarly solid immunity after a single
hepatitis A vaccination as shown here for natural infections,
supporting current trends for simplified, i.e. single-dose hepatitis A
vaccination schedules [1,2,27,28].
Our study has several limitations. It is unclear whether our
results can be generalized to other parts of the country with other
HAV epidemiological patterns and socioeconomic and sanitary
conditions. Further data will be required to guide decisions on
appropriate local or national hepatitis A prevention strategies.
Conducting repeated cross-sectional seroprevalence surveys in well
targeted age-groups is a simple approach to obtain estimates of the
incidence of new infections [12–14]. Estimates derived from such
studies will only be accurate if the surveys are representative and
the infection quite common. If the incidence is very low then other
means of surveillance are more suited than sero-surveys. Accurate
knowledge about current incidence levels is important to assess the
success of prevention measures or to define the need for
adjustments of prevention measures. Also, longitudinal 1995/96
data were only available for 117 children and no corresponding
data were available from 2003. A further limitation of the analysis
was that the risk of infection could not be estimated for children
aged $7 years due to the high anti-HAV prevalence in this age
group. If the shift in infection towards higher ages continues, lower
anti-HAV prevalence in older children in the future may lead to a
wider applicability of the method. Although not explicitly assessed
in 1995, it is highly unlikely that any of the children screened for
the field efficacy trial [10] had received hepatitis A vaccine
beforehand as no such vaccine was licensed in Nicaragua at the
time. The use of two different ELISA’s with different, but WHO
standardised cut-off levels for seropositivity in 1995 and 2003
reflects the objectives of the two studies, i.e. screening for
seronegativity and quantitative measurement of antibody levels,
and should not have introduced any bias.
Figure 3. Age-specific seroprevalence, GMC and maximum values of anti-HAV antibodies in the 2003 cross-sectional sample. The
shaded bars (upper scale) represent seroprevalence rates; the diamonds (lower scale) indicate GMC with lines representing 95% confidence intervals.
* The seroprevalence of the 6–11 months old children is entirely due to maternal anti-HAV antibodies (see Table 2). ** The maximal concentration of
13700 mIU/mL was caused by one recent HAV infection. Three other anti-HAV positive children in this group had maternal anti-HAV with
concentrations of 26, 28 and 31 mIU/ml (see Table 2).
doi:10.1371/journal.pone.0087643.g003
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In conclusion, the conduct of repeated cross-sectional surveys
providing estimates of age-specific HAV antibody prevalence in
countries of intermediate or high hepatitis A endemicity can be
used to estimate the force of infection in a given population.
Conducted over longer time periods, this approach would find
potential use to monitor the impact of population-based public
health interventions, such as provision of safe drinking water or the
introduction of universal mass vaccination against hepatitis A in
low-to-middle income countries. Furthermore it can be inferred
from the quantitative anti-HAV antibody level results that contact
with circulating HAV during adulthood seems not to have a
boosting effect on antibody levels – as postulated in the past - once
protective immunity has been established by natural infection.
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